Yet, expressional regulation of SAA1 in the ovary and its role in the pathogenesis of ovarian IR in PCOS remain elusive.įollicular fluid, granulosa cells and peripheral venous blood were collected from PCOS and non-PCOS patients with and without IR to measure SAA1 abundance for analysis of its correlation with IR status. In addition to its role in inflammation, SAA1 may participate in IR development in peripheral tissues. Serum amyloid A1 (SAA1) is an acute phase protein produced primarily by the liver in response to inflammation. Insulin resistance (IR) contributes to ovarian dysfunctions in polycystic ovarian syndrome (PCOS) patients. In the present review, we have focused on the pathophysiology and major revolutions of insulin resistance and excessive levels of androgen in females with PCOS. Although many factors are involved, resistance to the insulin and enhanced level of androgen are considered the major causes of PCOS. However, the overexposure of androgen has direct and specific influence on the development of insulin resistance. Endometrial cancer is also a serious concern which is reported with exceedingly high incidence in women with PCOS. It has been reported previously that PCOS is related to cardiac metabolic miseries and potently increases the risk of heart diseases. The overexposure of androgen is directly linked with insulin resistance and hyperinsulinaemia. It is clear that there is noteworthy elevation of androgen in PCOS, causing substantial misery and infertility problems. There are different pathophysiological factors involved in PCOS, and they play a major role in various abnormalities in individual patient. At reproductive stage of women, the rate of PCOS occurrence is measured as 6–10% and the prevalence rate may be double. The polycystic ovary syndrome (PCOS) is the disease featured by elevated levels of androgens, ovulatory dysfunction, and morphological abnormalities. Liraglutide appears superior to the other drugs in reducing weight and waist circumference. Data for waist‐to‐hip ratio were only available for metformin, which had no significant effect. Liraglutide alone, liraglutide/metformin and metformin alone significantly reduced waist circumference, but no change was found with orlistat. The amount of weight lost differed significantly among the drugs (in descending order): liraglutide, orlistat and metformin. Twenty‐three trials reporting on 941 women were included in the network meta‐analysis. Registration number: PROSPERO CRD 42017076625. Individually randomized, parallel group trials that evaluated the effects of these pharmacological treatments among adults or adolescents with PCOS and overweight/obesity, compared with a placebo or metformin group, were considered eligible. The objective of this study is to compare the effectiveness of metformin, inositol, liraglutide and orlistat to induce weight loss in women with PCOS and overweight/obesity.Ī search was conducted using the MEDLINE, EMBASE, PubMed and CENTRAL databases. However, we have no specific interventions to induce weight loss so far and rely on drugs used to treat other symptoms of the syndrome or obesity in the general population. Women with polycystic ovary syndrome (PCOS) are almost three times more likely to be obese than those without PCOS. miR-141-3p might play a role in glucose and lipid metabolism in PCOS-obese patients by targeting PTEN. In conclusion, miR-141-3p was downregulated in PCOS patients and had higher diagnostic value on PCOS and associated with glucose and lipid metabolism. PTEN was upregulated in PCOS patients and negatively correlated with miR-141-3p. Indexes of PCOS-obese patients were improved and miR-141-3p was upregulated after fat reduction intervention. Levels of glucose and lipid metabolism indexes were increased while HDL-C level was decreased in miR-141-3p low expression group. Area under ROC curve of miR-141-3p diagnosing PCOS-obese patients was 0.985 with specificity 95.35% and flexibility 93.33%. miR-141-3p was downregulated in PCOS patients. WHR and levels of TG, HDL-C, FBG, FINS, HOMA-β, and HOMA-IR showed significant differences in PCOS patients. Expressions of miR-141-3p and PTEN were detected. A 3-month fat reduction intervention was conducted to PCOS-obese patients. Clinical parameters and glucose and lipid indexes were analyzed. A total of 100 PCOS patients and 100 healthy controls were enrolled in this study. This study intended to investigate miR-141-3p expression in serum of PCOS patients and its correlation with glucose and lipid metabolism. miR-141-3p downregulation was reported in PCOS rats. Polycystic ovary syndrome (PCOS) is a common endocrinopathy with high prevalence.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |